Oncology

Top Medical News
Which factors predict mortality in advanced HCC?
10 hours ago
A study has found the high bilirubin, pretreatment hypoalbuminemia, and biochemical tests indicative of hepatic or renal dysfunctions are independently associated with short-term mortality in patients with advanced hepatocellular cancer (HCC) receiving atezolizumab and bevacizumab (Atezo/Bev).
Nivolumab plus ipilimumab superior to sunitinib in advanced RCC
Stephen Padilla, 11 hours ago
First-line treatment with nivolumab plus ipilimumab (NIVO+IPI) results in better survival and response benefits in patients with advanced renal cell carcinoma (aRCC) when compared with sunitinib (SUN), as shown by long-term follow-up data from the CheckMate 214 trial.
Interactive multistage robotic positioner for intraoperative MRI-guided stereotactic neurosurgery
Sarah Cheung, 15 hours ago

A joint multidisciplinary team of researchers from the Chinese University of Hong Kong (CUHK), the University of Hong Kong (HKU), University College London, and Johns Hopkins University has developed an interactive, multistage robotic positioner for intraoperative MRI-guided stereotactic neurosurgery aimed at treating patients with neurological diseases, such as brain tumours and Parkinson’s disease.

SBRT on par with HART in limited-stage small cell lung cancer
Yesterday
Stereotactic body radiotherapy (SBRT) is a safe and effective alternative to hyperfractionated accelerated radiotherapy (HART) in the treatment of limited-stage small-cell lung cancer (LS-SCLC), suggests a recent study.
Pembrolizumab plus lenvatinib effective against nonclear cell RCC
Stephen Padilla, Yesterday
Pembrolizumab (pembro) plus lenvatinib (lenva) provides durable antitumour activity in patients with advanced nonclear cell renal cell carcinoma (nccRCC) and has a manageable safety profile, according to the results of the phase II KEYNOTE-B61 study.
TKI-ICI combo offers hope for prostate cancer patients with poor prognosis
Audrey Abella, Yesterday
A combination of the TKI* cabozantinib and ICI** atezolizumab improved progression-free survival (PFS) in men with metastatic castration-resistant prostate cancer (mCRPC) with measurable extrapelvic nodal or visceral metastasis who progressed on prior novel hormonal therapy (NHT), findings from the phase III CONTACT-02 trial have shown.
Adjuvant pembrolizumab holds promise in bladder cancer
Audrey Abella, 2 days ago
The phase III AMBASSADOR Alliance A031501 trial showed a statistically significant and clinically meaningful improvement in disease-free survival (DFS) with adjuvant pembrolizumab compared with observation in patients with high-risk locally advanced muscle-invasive urothelial carcinoma (MIUC) after radical surgery regardless of PD-L1 status.
Special Reports
Approaches to diagnosis and management of invasive aspergillosis and mucormycosis
31 Aug 2023
Invasive aspergillosis and mucormycosis are two of the most common mould infections, and a growing problem worldwide, particularly amongst those who are immunocompromised. Despite recent advances in the clinical understanding of these mould infections, the mortality rate can increase significantly if these infections are left untreated. Therefore, there is a need for early diagnosis and timely therapeutic intervention. However, diagnosis remains a major challenge owing to atypical or insidious clinical presentation in patients. In this symposium, Professor Cornely shares his insights on the diagnosis and management of invasive aspergillosis and mucormycosis and his recommendations for optimising patient outcomes, including his preferred evidence-based treatment options.
Redefining survival in 3L+ large B-cell lymphoma with axicabtagene ciloleucel
Dr. Matthew Frank, 26 Jul 2023

Singapore’s Health Sciences Authority recently approved axicabtagene ciloleucel (Yescarta) for the treatment of relapsed or refractory large B-cell lymphoma (LBCL) in adults after ≥2 lines of systemic therapy. Shedding light on this innovative therapy, Dr Matthew Frank, Assistant Professor of Medicine specializing in Blood and Marrow Transplantation and Cellular Therapy at Stanford University, Stanford, California, US, discussed landmark trial data, some real-world evidence, and their implications for patient selection and adverse event management during the Yescarta Commercial Launch in Singapore in May.

Benefits of 1L ribociclib extend across MONALEESA studies
Dr. Erika Hamilton, 22 Jul 2023
First-line (1L) treatment with the CDK4/6 inhibitor ribociclib plus endocrine therapy (RIB + ET) confers consistent benefits in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer in the pooled analysis of the MONALEESA-2, -3, and -7 studies presented at the San Antonio Breast Cancer Symposium (SABCS) 2022.
CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma
Dr. Joshua Sasine, 15 Jul 2023
Diffuse large B-cell lymphoma (DLBCL) is the most frequently occurring subtype of non-Hodgkin lymphoma. Although curability is high following first-line immunochemotherapy, around 40 percent of patients will relapse or exhibit refractory disease, which dramatically reduces life expectancy. [Best Pract Res Clin Haematol 2018;31:209-216] Despite salvage chemo-immunotherapy and stem cell transplantation, patients with relapsed/refractory (R/R) DLBCL have a dismal prognosis. In the SCHOLAR-1 study, the median overall survival (OS) for refractory DLBCL was 6.3 months, the complete response rate was 7 percent, and the 1-year OS rate was 28 percent. [Blood 2017;130:1800-1808]
SARS-CoV-2 Variants: Everything you need to know
01 Feb 2023
The COVID-19 pandemic continues to evolve with the emergence of new SARS-CoV-2 variants. The variants of concern have the potential to impact the transmissibility, virulence, and clinical presentation of the disease, affecting the epidemiology, public health measures, and diagnostic and therapeutic options. Mutations in the spike protein of the virus have increased its ability to infect humans and evade neutralization by natural or immunisation-induced antibodies. The highly mutated Omicron variant of SARS-CoV-2 has multiple sublineages with varying transmissibility and immune evasion potential. Pre-exposure prophylaxis plays a crucial role in protecting the immunocompromised populations against severe disease; however, the rapidly changing landscape of the variants poses a major challenge to the current and future effectiveness of pre-exposure prophylactic monoclonal antibodies.
The Emerging Role of Biosimilars in Value-Based Medicine
01 Dec 2022
Biologic medicines and biosimilars
Biologic medicines are a category of very specific, highly effective medicines produced by a sophisticated and complex process involving living system1. Most of them are very large, complex molecules or mixtures of molecules, and many are produced using recombinant DNA technology. These medicines have revolutionised the treatment and prevention of many disabling and life-threatening diseases including cancers, Crohn’s disease, ulcerative colitis, diabetes, rheumatoid arthritis, osteoporosis, psoriasis, human immunodeficiency virus, multiple sclerosis, growth deficiencies, and more1.
Sotorasib offers a paradigm shift in the treatment of KRAS G12C-mutated NSCLC
Assoc Prof. Daniel SW Tan, Assoc Prof. Thomas John, 22 Nov 2022
Kirsten rat sarcoma viral oncogene (KRAS) mutations are common in non-small cell lung cancer (NSCLC) and are associated with poor prognosis, likely due to poor responses to most systemic therapies and lack of targeted therapies. At a recent webinar organized by Amgen, Associate Professor Daniel Tan from the National Cancer Centre, Singapore, gave an overview of the biomarker testing landscape in NSCLC. Associate Professor Thomas John from the Peter MacCallum Hospital, Australia, addressed the optimal treatment strategy for KRAS-mutant NSCLC and the role of sotorasib, a first-in-class RAS GTPase family inhibitor approved in Singapore for the treatment of adults with KRASG12C-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic therapy.

 

Conference Reports
Pembrolizumab plus lenvatinib effective against nonclear cell RCC
Stephen Padilla, 29 Feb 2024
Pembrolizumab (pembro) plus lenvatinib (lenva) provides durable antitumour activity in patients with advanced nonclear cell renal cell carcinoma (nccRCC) and has a manageable safety profile, according to the results of the phase II KEYNOTE-B61 study.
TKI-ICI combo offers hope for prostate cancer patients with poor prognosis
Audrey Abella, 29 Feb 2024
A combination of the TKI* cabozantinib and ICI** atezolizumab improved progression-free survival (PFS) in men with metastatic castration-resistant prostate cancer (mCRPC) with measurable extrapelvic nodal or visceral metastasis who progressed on prior novel hormonal therapy (NHT), findings from the phase III CONTACT-02 trial have shown.
Adjuvant pembrolizumab holds promise in bladder cancer
Audrey Abella, 28 Feb 2024
The phase III AMBASSADOR Alliance A031501 trial showed a statistically significant and clinically meaningful improvement in disease-free survival (DFS) with adjuvant pembrolizumab compared with observation in patients with high-risk locally advanced muscle-invasive urothelial carcinoma (MIUC) after radical surgery regardless of PD-L1 status.
KEYNOTE-564: Adjuvant pembrolizumab ups survival in kidney cancer
Elaine Soliven, 28 Feb 2024

Adjuvant treatment with pembrolizumab has significantly improved overall survival (OS) in patients with clear cell renal cell carcinoma (RCC) who are at high risk of recurrence after surgery, according to an updated analysis of the KEYNOTE-564 trial presented at ASCO GU 2024.

Durvalumab plus chemo for GC/GEJC delivers globally consistent benefit
Jairia Dela Cruz, 25 Feb 2024
Combination treatment with durvalumab plus FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) leads to higher rates of pathologic complete response (pCR) in patients with resectable gastric cancer (GC) or gastroesophageal junction cancer (GEJC), with the benefit universally observed regardless of geographic location, according to the subgroup analysis of the phase III MATTERHORN study.
Pembrolizumab delivers long-term survival benefits in advanced esophageal cancer
Stephen Padilla, 24 Feb 2024
First-line pembrolizumab (pembro) plus chemotherapy (chemo) in patients with untreated advanced esophageal cancer demonstrates robust efficacy after 5 years, with no new safety concerns, when compared with placebo plus chemo, according to a study presented at ASCO GI 2024.
Thoracoscopic esophagectomy better than open surgery in esophageal cancer
Stephen Padilla, 23 Feb 2024
Thoracoscopic esophagectomy (TE) has demonstrated its noninferiority to open transthoracic esophagectomy (OE) for patients with thoracic esophageal cancer in a study presented at ASCO GI 2024.
NGS could guide ovarian cancer treatment
Roshini Claire Anthony, 30 Mar 2020

The use of next generation sequencing (NGS) could help identify patients with ovarian cancer who would benefit from targeted therapies, according to a small retrospective study from Korea.